Klimed MK Sp. z o.o.
- Address
- lock Available on a paid plan
Klimed MK Sp. z o.o. - Multispecialty Clinical Research Center
Klimed MK Sp. z o.o. is a versatile clinical research facility conducting advanced Phase 3 trials across multiple therapeutic areas. The center demonstrates particular strength in neurodegenerative disorders, cardiovascular medicine, dermatology, and metabolic diseases, supporting the development of innovative therapeutic interventions for complex chronic conditions.
- Alzheimer's disease and early cognitive impairment studies with novel disease-modifying agents
- Heart failure with preserved ejection fraction (HFpEF) and cardiovascular outcomes research
- Dermatological conditions including moderate to severe atopic dermatitis
- Obesity management and cardiometabolic outcomes assessment
The research center specializes in evaluating disease-modifying therapies and long-term clinical outcomes, with expertise in conducting complex cardiovascular and renal endpoint trials. Their portfolio includes studies focused on atrial myopathy, clinical progression measures in dementia, and dermatological severity indices such as EASI (Eczema Area and Severity Index), demonstrating comprehensive capability in managing multifaceted trial protocols across diverse patient populations.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 6 therapeutic areas and 12 of 13 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
No sponsors linked to active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Eli Lilly & Co.3trials
lock +2 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Klimed MK Sp. z o.o.
lock Showing 1 of 11 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Oral Brepocitinib in Adults with Dermatomyositis | Priovant Therapeutics Inc. | Phase III | Not Recruiting | Nov 2022 | — |
IMP list
lock Showing 1 of 13 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Inclisiran | 2 | Unknown | 2023-09-04 | 2023-09-04 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.